Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,127.1
4.5 (0.15%)

 

  • STI Straits Times Index
    3,127.1
    4.5 (0.15%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,600.6
    6.0 (0.38%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,049.4
    -220.6 (-0.84%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,883.4
    3.1 (0.11%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,628.0
    9.4 (0.05%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,246.2
    -6.8 (-0.11%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,951.0
    -13.6 (-0.69%)
    Index delayed 20 minutes
  • XAO XAO
    6,593.0
    20.4 (0.31%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 642.8M
  • Value: 635.3M
  • Rise: 124
  • Fall: 153
  • Unch: 558

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
ThaiBev0.940+0.015
YZJ Shipbldg SGD0.935-0.030
SingTel3.250+0.060
Kep Infra Tr0.510-
Rex Intl0.076-0.001
Koh Eco0.053+0.002
RHT HealthTrust0.018-
Jadason^0.037+0.002
Frasers L&I Tr1.180-0.040

World Indices

World Indices
Name Last Change
Nasdaq 8,020.2 +71.7
HSI 26,044.6 -225.5
HSCEI 10,131.1 -46.2
Jakarta 6,246.0 -7.0
Nikkei 225 20,628.0 +9.4
SSE Comp 2,883.4 +3.1
Shanghai A 3,020.7 +3.3
Shanghai B 264.3 -0.5
PSE Comp 0.0
KOSPI 1,951.0 -13.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS MORPHOSYS AG SPONSORED ADR
Updated on 21 Aug 2019 (End of trading day)
Last (USD): 31.400 Change: +0.530 High: 31.710 Remarks: -
Change (%): +1.72 Low: 31.200
Open 31.590 Yesterday's Close 30.869999999999997
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 51,209 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.52033 Trailing EPS (USD) e -0.36634 NAV (USD) b 4.1403
PE a - Trailing PE f - Price / NAV b 7.5840
Dividend (USD) d - Cash In Hand (USD) g 0.4891 Issued & Paid-up Shares c 127,360,000
Dividend Yield (%) d - Price / Cash In Hand g 64.200 Treasury Shares h 1,020,656
Beta - 75 Daysi 0.933 R-Squared - 75 Days(%)i 7.87 Market Cap (M) 3,999.104
Beta - 500 Daysi 0.179 R-Squared - 500 Days (%)i 0.46 Enterprise Value (M) 3,657.985
Piotroski F Score 3 Exchange Code MOR Par Value ( $ ) n.a.
52 Weeks Volatility (%) 44.31 Free Float (%) -
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 09 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 14 Aug 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS NASDAQ 3,999.104 - - 7.5840 -
Industry Biotechnology NASDAQ 2,256.236 128.798 99.860 5.2205 0.784
Local Peer AMGEN INC NASDAQ 122,303.022 14.570 15.369 11.3306 2.718
Local Peer GILEAD SCIENCES INC NASDAQ 81,217.439 14.889 13.639 3.5911 3.599
Local Peer CELGENE CORP NASDAQ 67,812.339 16.760 12.865 6.7468 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 47,911.324 22.854 21.631 9.4500 -
Local Peer BIOGEN INC NASDAQ 43,009.351 9.707 8.124 3.3204 -
Local Peer ILLUMINA INC NASDAQ 42,703.500 51.699 45.526 9.8577 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,724.340 13.387 15.815 3.3543 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,750.229 331.831 19.309 2.5336 -
Local Peer INCYTE CORPORATION NASDAQ 18,510.817 169.060 60.519 8.2373 -
Local Peer EXACT SCIENCES CORP NASDAQ 15,438.497 - - 20.1671 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 14,037.596 - - 4.7409 -
Local Peer SEATTLE GENETICS INC NASDAQ 13,503.974 - - 10.6178 -
Other Local Peers IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), EXELIXIS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), FIBROGEN INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), UNIQURE N.V. (NASDAQ), NATERA INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), REGENXBIO INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), OPKO HEALTH INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), INTREXON CORP (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ARVINAS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), CORTEXYME INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), PERSONALIS INC (NASDAQ), AVROBIO INC (NASDAQ), NEXTCURE INC (NASDAQ), SYNTHORX INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), DERMIRA INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), MERUS B V (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CHEMOCENTRYX INC (NASDAQ), IMMUNOGEN INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AGENUS INC (NASDAQ), MEDICINOVA INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RESTORBIO INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), XBIOTECH INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), GERON CORP (NASDAQ), RECRO PHARMA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), KAMADA (NASDAQ), ATHERSYS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ARDELYX INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), AFFIMED N V (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), NOVAVAX INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), CHIMERIX INC (NASDAQ), XOMA CORP (NASDAQ), GLYCOMIMETICS INC (NASDAQ), IMV INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), TOCAGEN INC (NASDAQ), SYNLOGIC INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), VERASTEM INC (NASDAQ), SAVARA INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VACCINEX INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), COHBAR INC (NASDAQ), EQUILLIUM INC (NASDAQ), CURIS INC (NASDAQ), ORGENESIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ARAVIVE INC (NASDAQ), INFLARX N V (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), VERMILLION INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), IVERIC BIO INC (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), EVOGENE LTD (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), BIOCARDIA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), BIOCEPT INC (NASDAQ), SOLIGENIX INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), HISTOGENICS CORP (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), VICAL INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), PRECIPIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ATYR PHARMA INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ)
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 106,623.607 39.742 39.742 14.2485 1.138
Global Peer AGILENT TECHNOLOGIES INC NYSE 22,814.695 72.199 21.282 4.8061 0.831
Global Peer SINO BIOPHARM HKEx 132,820.777 12.396 12.724 3.8318 0.693
Global Peer WUXI BIO HKEx 102,801.168 137.635 107.600 10.5821 -
Global Peer BEIGENE HKEx 68,870.713 - - 5.6732 -
Global Peer GENSCRIPT BIO HKEx 33,590.660 202.016 202.011 8.9631 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer 3SBIO HKEx 31,227.851 20.643 20.643 3.1789 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,172.360 34.647 - 2.1967 -
Other Global Peers FRONTAGE (HKEx), VIVA BIOTECH (HKEx), HAOHAI BIOTEC (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), ASCLETIS-B (HKEx), AVITA MEDICAL LTD (ASX), MESOBLAST LTD (ASX), CKLIFE SCIENCES (HKEx), ESSEX BIO-TECH (HKEx), NEXT SCIENCE LTD (ASX), KADMON HLDGS INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), LEE'S PHARM (HKEx), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), PFENEX INC (NYSE American), LINEAGE CELL THERAPEUTICS INC (NYSE American), ENZO BIOCHEM INC (NYSE), UNI-BIO GROUP (HKEx), PALATIN TECHNOLOGIES INC (NYSE American), BBI LIFE SCI (HKEx), STANDARD DIVERSIFIED INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), NEUREN PHARMACEUTICALS LTD (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), IBIO INC (NYSE American), CEL-SCI CORP (NYSE American), PORT (SET), RESAPP HEALTH LIMITED (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), PHYLOGICA LIMITED (ASX), IMMUTEP LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), SYNTHETIC BIOLOGICS INC (NYSE American), IMUGENE LIMITED (ASX), CT ENTERPRISE (HKEx), REGENT PACIFIC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), ORTHOCELL LIMITED (ASX), ZELDA THERAPEUTICS LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), BIOTRON (ASX), ONCOSIL MEDICAL LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), MEMPHASYS LTD (ASX), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), ALTERITY THERAPEUTICS LIMITED (ASX), PATRYS LIMITED (ASX), REGENEUS LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), BIONOMICS LTD (ASX), IMMURON LIMITED (ASX), Suntar Eco-City^ (SGX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), NANOVIRICIDES INC (NYSE American), CELLMID LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), GENETIC TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), BIOXYNE LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ANATARA LIFESCIENCES LTD (ASX), MGRC (Bursa), QT Vascular (SGX), ACTINOGEN MEDICAL LTD (ASX), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NOVITA HEALTHCARE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), MEDIBIO LIMITED (ASX), ALCHEMIA LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+1.480
+4.95 %
10 Days --0.180
-0.57 %
20 Days -+2.010
+6.84 %
Medium Term Return 3 Months -+5.560
+21.52 %
6 Months -+4.950
+18.71 %
1 Year -+1.950
+6.62 %
Annualised Return Annualised --
+6.62 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 21.750 - 31.960 Change From 1 Year Low +9.650 % Change From 1 Year Low (%) +44.37
Change From 1 Year High -0.560 % Change From 1 Year High (%) -1.75
2 Years Range 21.750 - 35.900 Change From 2 Years Low +9.650 % Change From 2 Years Low (%) +44.37
Change From 2 Years High -4.500 % Change From 2 Years High (%) -12.53
5 Years Range 21.750 - 35.900 Change From 5 Years Low +9.650 % Change From 5 Years Low (%) +44.37
Change From 5 Years High -4.500 % Change From 5 Years High (%) -12.53
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Aug 2019 31.590 31.710 31.200 31.400 51,209 -
20 Aug 2019 31.130 31.130 30.595 30.870 31,307 -
19 Aug 2019 30.900 30.900 30.550 30.690 46,281 -
16 Aug 2019 29.870 30.190 29.830 30.050 43,048 -
15 Aug 2019 29.500 30.000 29.360 29.920 42,976 -
14 Aug 2019 30.020 30.180 29.430 29.520 52,895 -
13 Aug 2019 30.160 30.760 30.120 30.610 56,525 -
12 Aug 2019 30.830 30.980 30.000 30.070 87,820 -
09 Aug 2019 31.120 31.260 30.950 31.060 59,305 -
08 Aug 2019 31.340 31.960 31.210 31.580 153,002 -
07 Aug 2019 30.200 30.790 28.630 30.410 253,982 -
06 Aug 2019 29.420 29.530 28.930 29.050 85,206 -
05 Aug 2019 29.570 29.620 28.570 28.880 67,473 -
02 Aug 2019 29.980 29.980 29.340 29.560 64,617 -
01 Aug 2019 29.970 30.610 29.835 29.930 42,362 -
31 Jul 2019 30.120 30.460 29.785 30.030 54,568 -
30 Jul 2019 29.880 30.090 29.690 30.020 65,296 -
29 Jul 2019 30.600 30.610 30.350 30.580 80,102 -
26 Jul 2019 29.750 29.860 29.570 29.750 121,532 -
25 Jul 2019 30.030 30.100 29.290 29.390 217,985 -
24 Jul 2019 29.940 30.240 29.800 29.800 347,227 -
23 Jul 2019 29.000 29.140 28.815 28.880 157,870 -
Summary
Current 2 Weeks
(08 Aug 2019 to 21 Aug 2019)		 31.340 31.960 29.360 31.400 624,368 -
Previous 2 Weeks
(25 Jul 2019 to 07 Aug 2019)		 30.030 31.960 29.290 30.410 1,053,123 -
4 Weeks from
(26 Jun 2019 to 24 Jul 2019)		 23.670 31.960 23.420 29.800 1,670,028 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.